Explanipedia

Author Correction: Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injury Open

Kerri D. Pryce, Randal A. Serafini, Aarthi Ramakrishnan, Andrew Nicolais, Ilinca M. Giosan , et al. · 2024

A randomized, double-blind, placebo-controlled study of histone deacetylase type 6 inhibition for the treatment of painful diabetic peripheral neuropathy Open

David Michelson, William W. Chin, Robert H. Dworkin, Roy Freeman, David N. Herrmann , et al. · 2023

Introduction: Current treatments for painful diabetic peripheral neuropathy (DPN) are insufficiently effective for many individuals and do not treat nonpain signs and symptoms. The enzyme histone deacetylase type 6 (HDAC6) may play a role …

HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease Open

Sandra Bráz, Marlene M. Morgado, Marta Pereira, Ana C. Monteiro, Olga Golonzhka , et al. · 2023

Introduction In Krabbe disease (KD), mutations in β-galactosylceramidase (GALC), a lysosomal enzyme responsible for the catabolism of galactolipids, leads to the accumulation of its substrates galactocerebroside and psychosine. This neurol…

Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injury Open

Kerri D. Pryce, Randal A. Serafini, Aarthi Ramakrishnan, Andrew Nicolais, Ilinca M. Giosan , et al. · 2023

HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease Open

Sandra Bráz, Marlene M. Morgado, Marta Pereira, Ana Monteiro, Olga Golonzhka , et al. · 2023

In Krabbe disease (KD), mutations in β-galactosylceramidase (GALC), a lysosomal enzyme responsible for the catabolism of galactolipids, lead to the accumulation of its substrates galactocerebroside and psychosine. This neurologic condition…

Valproate reverses mania-like behaviors in mice via preferential targeting of HDAC2 Open

Ryan W. Logan, Angela R. Ozburn, Rachel N. Arey, Kyle D. Ketchesin, Alicia Winquist , et al. · 2020

Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus Open

Jingjing Ren, Michelle D. Catalina, Kristin Eden, Xiaofeng Liao, Kaitlin A. Read , et al. · 2019

Autoantibody production by plasma cells (PCs) plays a pivotal role in the pathogenesis of systemic lupus erythematosus (SLE). The molecular pathways by which B cells become pathogenic PC secreting autoantibodies in SLE are incompletely cha…

Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model Open

Elisabeth Rossaert, Eveliina Pollari, Tom Jaspers, Lawrence Van Helleputte, Matthew Jarpe , et al. · 2019

Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment Open

Jiacheng Ma, XiaoJiao Huo, Matthew Jarpe, Annemieke Kavelaars, Cobi J. Heijnen · 2018

Chemotherapy-induced cognitive impairment (CICI) is a commonly reported neurotoxic side effect of chemotherapy, occurring in up to 75% cancer patients. CICI manifests as decrements in working memory, executive functioning, attention, and p…

Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth Open

Lawrence Van Helleputte, Mandy S. J. Kater, Dana P. Cook, Caroline Eykens, Elisabeth Rossaert , et al. · 2017

HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients Open

Wenting Guo, Maximilian Naujock, Laura Fumagalli, Tijs Vandoorne, Pieter Baatsen , et al. · 2017

HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia Open

S Tharkar-Promod, Danielle P. Johnson, Samuel Bennett, Emily Dennis, B G Banowsky , et al. · 2017

Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL) expressing BCR-ABL1 oncoprotein is a major subclass of ALL with poor prognosis. BCR-ABL1-expressing leukemic cells are highly dependent on double-st…

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia Open

Chengyin Min, Nathan W. Moore, Jeffrey R. Shearstone, Steven N. Quayle, Pengyu Huang , et al. · 2017

Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic stem cell disorders characterized by defects in myeloid differentiation and increased proliferation of neoplastic hematopoietic precursor cells. Outcomes for patients w…

Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot–Marie–Tooth Disease Open

Veronick Benoy, Pieter Vanden Berghe, Matthew Jarpe, Philip Van Damme, Wim Robberecht , et al. · 2016

Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, with an estimated prevalence of 1 in 2500. The degeneration of motor and sensory nerve axons leads to motor and sensory symptoms that progress over time …

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models Open

Pengyu Huang, Ingrid Almeciga-Pinto, Matthew Jarpe, John H. van Duzer, Ralph Mazitschek , et al. · 2016

ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242). Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the pote…

Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2 Open

Jeffrey R. Shearstone, Olga Golonzhka, Apurva Chonkar, David Tamang, John H. van Duzer , et al. · 2016

Therapeutic intervention aimed at reactivation of fetal hemoglobin protein (HbF) is a promising approach for ameliorating sickle cell disease (SCD) and β-thalassemia. Previous studies showed genetic knockdown of histone deacetylase (HDAC) …

Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice Open

Nicole Regna, Miranda D. Vieson, Xin Luo, Cristen B. Chafin, Abdul Gafoor Puthiyaveetil , et al. · 2015

We sought to determine if a selective HDAC6 inhibitor (ACY-738) decreases disease in NZB/W mice. From 22 to 38weeks-of-age, mice were injected intraperitoneally with 5 or 20mg/kg of ACY-738, or vehicle control. Body weight and proteinuria …

Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY‐738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice Open

Tabassum Majid, Deric M. Griffin, Zachary K. Criss, Matthew Jarpe, Robia G. Pautler · 2015

Introduction Current therapy for Alzheimer's disease (AD) focuses on delaying progression, illustrating the need for more effective therapeutic targets. Histone deacetylase 6 (HDAC6) modulates tubulin acetylation and has been implicated as…

Matthew Jarpe YOU? Author Swipe